Webinars

In the landscape of the clinical trial industry in 2024, persistent challenges persist in the realms of patient recruitment and retention.

Clinical trial patient recruitment and retention remains one of the key challenges to successfully bringing a new therapeutic to market. An estimated 85% of clinical trials face delays due to enrolment issues [1,2], and poor recruitment is a common reason for discontinuation [3]. Of those successfully enrolled, around 30% are likely to drop out [4], which increases costs for sponsors and threatens the viability of the trial itself.

Putting the patient first has never been higher up the agenda throughout the drug development process, but can we further fine-tune our approach? Tune into this webinar where we ask: • How important is early patient engagement to business success. • How do you ensure the patient voice is as ‘loud’ in later stages • Whose responsibility is it to ensure the patient voice is heard Viewers will come out with a deeper understanding of how to best keep the patient voice alive through all stages of drug development.

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in extra financial costs for sponsors and potentially placing the future of the trial in jeopardy.

In this webinar Langland will speak to Jonathan Moshinsky, Co-Founder and CEO of Stitch, a technology start-up supporting participant retention by enabling in-study feedback, and Sofia Fionda, Co-Founder of Boxee Group, a healthcare specialist market research agency with expertise in uncovering what motivates people to take part in trials. Join us to explore the why, how and what of improving the clinical experience for participants, sites, and sponsors.

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients – and therefore more robust data – but also promotes health equity and research and innovation across continents.

Mark and Urs will be discussing the pros and cons of an enterprise-wide approach to patient centricity, and explore the measurable benefits it could deliver. • Who should be involved in patient centric initiatives? • Should organisations focus their energies (and budget) on customer-facing or medical colleagues – or is there a benefit to including other functions?

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments.

Value-based contracts (VBC) are increasingly considered by companies for many types of therapies. Some companies are suggesting that VBC will become the default for them across their portfolio.

COVID-19 has had a huge impact on how we all think and act. Our working environments may look very different now to the way they did pre-pandemic, and not all the changes have been negative.

Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to market.